Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03519230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

StatusActive, Not Recruiting
PhasePhase 3
SponsorBeiGene
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv20
  2. Primary completion date changed from estimate of Jun 30, 2026 to Dec 1, 2025 Completion date: Jun 30, 2027 to Jan 30, 2027v19 Show 1 more changeShow less
    • Completion date: Jun 30, 2027 to Jan 30, 2027
  3. Primary completion date: Jun 30, 2025 to Jun 30, 2026 Primary endpoint revised · Completion date: Jun 30, 2026 to Jun 30, 2027 · Secondary endpoints: 3 to 6v18 Show 3 more changesShow less
    • Primary endpoint revised
    • Completion date: Jun 30, 2026 to Jun 30, 2027
    • Secondary endpoints: 3 to 6

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites revised (28)v17 See this version in full on ClinicalTrials.gov ↗
  5. Enrollment target: estimated 216 to confirmed 224v16
Show 14 earlier versionsHide 14 earlier versions
  1. 2 versions Re-verified since Aug 1, 2023, no change to tracked fieldsv14-v15
  2. Primary completion date: Jun 30, 2022 to Jun 30, 2025v13
  3. Re-verified, no change to tracked fieldsv12
  4. Primary completion date: Apr 30, 2021 to Jun 30, 2022 Completion date: Apr 30, 2021 to Jun 30, 2026 · Study sites revised (28)v11 Show 2 more changesShow less
    • Completion date: Apr 30, 2021 to Jun 30, 2026
    • Study sites revised (28)

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Apr 30, 2020 to Apr 30, 2021 Completion date: Feb 28, 2021 to Apr 30, 2021 · Eligibility criteria expanded, about 10 words · Study title revisedv10 Show 3 more changesShow less
    • Completion date: Feb 28, 2021 to Apr 30, 2021
    • Eligibility criteria expanded, about 10 words
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  6. 2 versions Re-verified since Oct 30, 2019, no change to tracked fieldsv8-v9
  7. Trial status: Recruiting to Active, Not Recruiting Site details revised at 28 of 28 sitesv7 Show 1 more changeShow less
    • Site details revised at 28 of 28 sites
  8. Start date: Apr 25, 2018 to May 14, 2018v6
  9. Re-verified, no change to tracked fieldsv5
  10. Primary endpoints: 2 to 1 Study sites: 27 to 28 · Primary completion date: Mar 31, 2020 to Apr 30, 2020 · Secondary endpoints revised (3) · 1 morev4 Show 4 more changesShow less
    • Study sites: 27 to 28
    • Primary completion date: Mar 31, 2020 to Apr 30, 2020
    • Secondary endpoints revised (3)
    • Study title shortened, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  11. Primary endpoints: 1 to 2 Study sites: 4 to 27 · Interventions: BGB-290 capsule (Drug), Placebo capsule (Drug) to Pamiparib capsule (Drug), Placebo capsule (Drug) · Eligibility criteria revised · 2 morev3 Show 5 more changesShow less
    • Study sites: 4 to 27
    • Interventions: BGB-290 capsule (Drug), Placebo capsule (Drug) to Pamiparib capsule (Drug), Placebo capsule (Drug)
    • Eligibility criteria revised
    • Secondary endpoints revised (3)
    • Study title expanded, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  12. Study title shortened, about 7 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BeiGene
37 trials monitored
See 1 trial at risk
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Trial Details
NCT Number NCT03519230
Lead Sponsor BeiGene
Conditions Ovarian Cancer
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov